|
|
|
|
|
HONG KONG, Oct 19, 2016 - (ACN Newswire) - PuraPharm Corporation Limited ("PuraPharm" or the "Group", HK:1498), a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of Concentrated Chinese Medicine Granules ("CCMG") products under the "Nong's" brand, is delighted to announce that it has been awarded "Corporate Achievement Award" at the Outstanding Import and Export Enterprise Awards 2016 yesterday. The award is certainly an acknowledgement of the Group's outstanding performance in business development and market expansion, and an affirmation to the society-wide and industry-wide recognitions of the Group's products and achievements.
 | | PuraPharm Corporation Limited wins Corporate Achievement Award at
Outstanding Import & Export Enterprise Awards 2016.
Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm (2nd from left) receives the award on stage. |
Organised by the Hong Kong Chinese Importers' & Exporters' Association, the award aims to promote and recognise the tremendous efforts and contributions made by import and export enterprises for the betterment of Hong Kong?s economic development. Since its establishment, the association has been committed to promoting trade between local enterprises and other businesses overseas through organising activities such as economic forums and seminars in order to share the latest business information to industry players.
Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm, said, "We are very honoured and inspired to have received the Corporate Achievement Award, owed very much to the contributions of our team over the years. As Hong Kong's largest supplier of CCMG products, we are committed to achieving our goal of modernising Chinese medicine. To strengthen the Group's competitive advantages, we have been developing and introducing new products and also actively enhancing PuraPharm and Nong's brand recognition in China and overseas.
"The rapid expansion of Nong's clinic is also a proof of our success. In addition to opening more Nong's Chinese medicine clinics in Hong Kong, we will also replicate the successful clinic business model in China and overseas markets. We plan to open our first Nong's Chinese medicine clinic in Toronto, Canada and our first Nong's Chinese medicine clinic in Nanning, Guangxi Zhuang Autonomous Region within this year, along with the number of clinics in Hong Kong reaching the significant benchmark of 50 by end of this year."
Mr. Chan added, "On top of expanding the clinic network, PuraPharm has broadened the market coverage in order to boost its sales network and deepen market penetration, enabling the distribution of CCMG products to more cities and increase its market share. The Group has also strengthened its supply chain management to ensure it has a solid foundation to support its long term business growth and development. With the experienced management team and sophisticated product development capabilities, we will continue to capitalise on the huge demand for Chinese medicine and the business opportunities brought by CCMG products, and will continue to push towards our goal of modernising Chinese medicine and putting it on the map of the world."
About PuraPharm Corporation Limited
PuraPharm is a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of CCMG products which the Group markets under its "Nong's(R)" brand. PuraPharm is the largest supplier of CCMG products in Hong Kong with a market share of 70% in terms of prescription revenue for the Hong Kong CCMG product market in 2014, according to the Euromonitor Report. The Group also sells a broad range of general Chinese healthcare products, such as PuraGold(R) and Oncozac(R), which are essentially Chinese herbal supplements, on an OTC basis, targeting end-consumers. PuraPharm currently operates 46 Nong's(R) clinics in Hong Kong. PuraPharm's shares have been listed on the Main Board of the Stock Exchange of Hong Kong Limited since 8 July 2015 under the stock code 1498.
Media Enquiries:
Strategic Financial Relations Limited
Heidi So, +852 2864 4826, heidi.so@sprg.com.hk
Janet Fong, +852 2864 4817, janet.fong@sprg.com.hk
www.sprg.com.hk
Topic: Awards
Source: PuraPharm Corporation Limited
Sectors: Food & Beverage
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
